TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22835841
Drug: Extinction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extinction treatment in one context (B)
Study: 20555288
Drug: Estrogen +
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen + Testosterone (40 mg testosterone undecanoate)
Study: 18482290
Drug: DHEA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA supplementation (50 mg daily for 1 year)
Study: 10501246
Drug: Intranasal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal vaccine composed of native outer membrane vesicles (NOMV)
Study: 28590525
Drug: Repeated injections
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated injections of abobotulinumtoxinA
Study: 27039205
Drug: White wine
Normalized name: White wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: White wine with ≤15% alcohol content twice a day for 3-4 weeks
Study: 27039205
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (such as Boost® or Ensure®)
Study: 24413342
Drug: Mindfulness treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness treatment
Study: 21122516
Drug: Oral plus
Normalized name: Acetaminophen/Dexbrompheniramine Maleate/Pseudoephedrine Hydrochloride 500 MG-3 MG-60 MG Oral Tablet, Extended Release [DRIXORAL PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral plus enema mesalazine treatment (PINCE)
Study: 21122516
Drug: Oral mesalazine
Normalized name: mesalamine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mesalazine treatment alone (Control)
Study: 16269638
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus thermal stimulation (TS) for 30 minutes daily for 6 weeks
Study: 16269638
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus thermal stimulation (TS)
Study: 12412828
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of mycophenolate mofetil alone (treatment 1)
Study: 12412828
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of mycophenolate mofetil and 2400 mg of calcium polycarbophil (treatment 2)
Study: 12412828
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of mycophenolate mofetil and 2400 mg of calcium polycarbophil with 30 mg of lansoprazole for 5 days (treatment 3)
Study: 9706948
Drug: Tramadol (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (1.25 mg/kg)
Study: 9706948
Drug: Morphine (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.125 mg/kg)
Study: 312297
Drug: salsalate (salicylsalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: salsalate (salicylsalicylic acid) 3000 mg
Study: 312297
Drug: aspirin 3900
Normalized name: aspirin 3900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin 3900 mg
Study: 19337257
Drug: Immunochemical faecal
Normalized name: Enterococcus faecalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunochemical faecal occult blood testing (FIT) at cut-off 75 ng/ml
Study: 19337257
Drug: Immunochemical faecal
Normalized name: Enterococcus faecalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunochemical faecal occult blood testing (FIT) at varying cut-off levels (50-200 ng/ml)
Study: 3521767
Drug: Adjuvant tamoxifen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant tamoxifen, 40 mg daily for three years
Study: 30307466
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg daily) and palbociclib (125 mg daily, 3 weeks/4) during 19 weeks
Study: 30307466
Drug: Chemotherapy (FEC100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (FEC100 followed by docetaxel)
Study: 26454185
Drug: Behavioral activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral activation (5 weekly sessions)
Study: 25391006
Drug: RBV for
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV for 4 weeks followed by combined therapy with peg‐IFN alpha‐2a + RBV for 48 weeks (n = 73)
Study: 25391006
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with peg‐IFN alpha‐2a + RBV for 48 weeks (n = 30)
Study: 20844613
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of 150 × 10^6 autologous bone marrow mononuclear cells
Study: 16012273
Drug: SNRI antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNRI antidepressants
Study: 12651759
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid tablets (Aminogran Food Supplement, UCB)
Study: 12651759
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid tablets
Study: 10820174
Drug: Furosemide 120
Normalized name: furosemide 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 120 mg alone
Study: 10820174
Drug: Furosemide 120
Normalized name: furosemide 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 120 mg plus sulfisoxazole
Study: 6151343
Drug: Prizidilol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prizidilol (200 mg X 2)
Study: 6151343
Drug: Carvedilol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25 mg and 50 mg)
Study: 6151343
Drug: Carvedilol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25 mg X 2 and 50 mg X 2)
Study: 1350491
Drug: Carvedilol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (50 mg)
Study: 6151343
Drug: Prizidilol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prizidilol (400 mg)
Study: 21730017
Drug: SB-649868 (10-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-649868 (10-80 mg single dose)
Study: 21730017
Drug: SB-649868 (5-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-649868 (5-30 mg multiple repeat dose)
Study: 21730017
Drug: SB-649868 (evening
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-649868 (evening dosing)
Study: 18946429
Drug: Thiopentone and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone and ketamine combination (Group III)
Study: 17311602
Drug: Ipratropium 40
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium 40 microg by inhalation (positive control)
Study: 17311602
Drug: Oral loperamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral loperamide 4 mg
Study: 11294513
Drug: Percutaneous estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous estradiol gel 1.25 g (0.75 mg E2)
Study: 11294513
Drug: Percutaneous estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous estradiol gel 2.5 g (1.5 mg E2)
Study: 11294513
Drug: Percutaneous estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous estradiol gel 0.625 g (0.375 mg E2)
Study: 11294513
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol patch delivering 0.05 mg E2 per day
Study: 9767555
Drug: Triple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple drug immunosuppressive regimen including CsA, azathioprine and corticosteroids
Study: 9767555
Drug: Quadruple sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple sequential combination of rabbit antithymocyte globulin (ATG) for 10 days, azathioprine, corticosteroids and delayed CsA
Study: 7874660
Drug: Marital therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marital therapy alone
Study: 7874660
Drug: Marital therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marital therapy in combination with antidepressants
Study: 3396702
Drug: High-dosage testosterone
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage testosterone enanthate (TE) for 5 to 6 months
Study: 3396702
Drug: Placebo (sesame
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sesame oil) injections for 5 to 6 months
Study: 30791735
Drug: Yoga therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga therapy (60 minutes once a week for 8 weeks)
Study: 24060261
Drug: Arthritis-specific demographics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthritis-specific demographics (type, medication use)
Study: 24060261
Drug: Older age,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older age, less than a high school education, rheumatoid arthritis, greater arthritis duration, taking steroids, taking narcotics, greater pain, greater stiffness, greater depressive symptoms, lower arthritis self-efficacy
Study: 21428240
Drug: Olanzapine film-coated
Normalized name: olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine film-coated tablet (test formulation)
Study: 21428240
Drug: Olanzapine orodispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine orodispersible tablet (test formulation)
Study: 21428240
Drug: Reference formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulations (brand formulations)
Study: 11963648
Drug: Lidose formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidose formulation of fenofibrate (67 mg)
Study: 11963648
Drug: Lidose formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidose formulation of fenofibrate (200 mg)
Study: 11963648
Drug: Reference micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference micronized formulation of fenofibrate (67 mg)
Study: 11963648
Drug: Reference micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference micronized formulation of fenofibrate (200 mg)
Study: 2541159
Drug: Cortisol (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (6 mg/h)
Study: 30941975
Drug: Knowledge about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge about PCa treatment success
Study: 27874307
Drug: Needle-free injection
Normalized name: Stratis Needle-Free Injection Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-free injection device
Study: 21947374
Drug: Combined spa
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined spa therapy (mud packs and thermal baths) and rehabilitation (exercises in a thermal pool) for 10 sessions
Study: 17542112
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron treatment (5 mg elemental iron as ferrous sulfate per kg of body weight)
Study: 17542112
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron treatment (5 mg elemental iron as ferrous sulfate per kg of body weight)
Study: 17542112
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly iron treatment (5 mg elemental iron as ferrous sulfate per kg of body weight)
Study: 9169251
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin formulation
Study: 9169251
Drug: Plain paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain paracetamol
Study: 9169251
Drug: Soluble paracetamol
Normalized name: Disprol Soluble Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble paracetamol
Study: 8192173
Drug: 0.5% podofilox
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% podofilox self-administered twice daily for 3 consecutive days per week for 4 weeks (stage 1)
Study: 8192173
Drug: 0.5% podofilox
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% podofilox self-administered once daily for 3 days per week for 8 weeks (stage 2)
Study: 3285883
Drug: Amoxycillin‐clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin‐clavulanic acid (1.2 g intravenous)
Study: 3285883
Drug: Metronidazole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (1 g suppository)
Study: 22935052
Drug: Domperidone 10
Normalized name: domperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 10 mg orally three times daily for 28 days
Study: 28107101
Drug: Placebo 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days
Study: 25742888
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg enalapril plus 0.8 mg FA (high‐FA group)
Study: 25742888
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg enalapril (control group)
Study: 25742888
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg enalapril plus 0.4 mg FA (low‐FA group)
Study: 23004926
Drug: Methantheline bromide
Normalized name: methantheline bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methantheline bromide (MB) 50 mg three times daily
Study: 24004119
Drug: Low-dose helical
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose helical computed tomography (CT)
Study: 10971659
Drug: 6-mg Sirdalud
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mg Sirdalud
Study: 10971659
Drug: 12-mg Sirdalud
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-mg Sirdalud MR
Study: 8884967
Drug: Conventional 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 5 days per week treatment (arm B)
Study: 1571205
Drug: Prednisone, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone, 40 mg/m2, given every other day as a single morning dose
Study: 1571205
Drug: Lactose, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose, 40 mg/m2, given every other day as a single morning dose (Control)
Study: 3880781
Drug: Local application
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local application of dimethylsulfoxide (DMSO) solution
Study: 25005452
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg orally once daily
Study: 25005452
Drug: Dose-adjusted oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-adjusted oral vitamin K antagonist (VKA)
Study: 11879260
Drug: Sildenafil (100-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (100-mg single dose)
Study: 9226059
Drug: loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: loratadine (10 mg OD)
Study: 7904786
Drug: Roxatidine acetate
Normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxatidine acetate (150 mg once daily)
Study: 3523713
Drug: trimethoprim‐sulfamethoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethoprim‐sulfamethoxazole (160 mg/800 mg daily)
Study: 3523713
Drug: trimethoprim (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethoprim (200 mg daily)
Study: 3523713
Drug: bicozamycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: bicozamycin (500 mg four times daily)
Study: 3523713
Drug: norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: norfloxacin (400 mg daily)
Study: 23442897
Drug: Dialectical behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behaviour therapy
Study: 29567630
Drug: Enalapril started
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril started before chemotherapy (prevention arm)
Study: 29567630
Drug: Enalapril started
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril started only in patients with an increase in troponin during or after chemotherapy (troponin-triggered arm)
Study: 29354992
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of cilostazol, 50 mg, twice a day for 4 sessions (2 weeks each session)
Study: 25736283
Drug: Evacetrapib 130
Normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib 130 mg/d following a high-fat breakfast
Study: 25736283
Drug: Evacetrapib 130
Normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib 130 mg/d following a 10-hour fast
Study: 25736283
Drug: Evacetrapib 130
Normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib 130 mg/d (both fed and fasted states)
Study: 21178093
Drug: Micronutrient powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient powder (MNP) containing 2.5 mg iron as NaFeEDTA and 2.5 mg zinc, added to high-phytate maize porridge 5 days/week for 23 weeks
Study: 19064623
Drug: RTS,S/AS02D vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS02D vaccine
Study: 10975476
Drug: Daily schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily schedule of plasmapheresis
Study: 9368546
Drug: Early outpatient
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early outpatient treatment for PTSD for 6 months
Study: 1391980
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with tamoxifen and medroxyprogesterone acetate
Study: 29940126
Drug: Conventional subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional subcutaneous insulin therapy
Study: 25609011
Drug: Zovirax 200
Normalized name: Zovirax 200mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zovirax 200 mg dispersible tablets co-administered with 400 mg chitosan HCl
Study: 25609011
Drug: Zovirax 200
Normalized name: Zovirax 200mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zovirax 200 mg dispersible tablets co-administered with 1000 mg chitosan HCl
Study: 23400856
Drug: Color characters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Color characters (e.g., hong2, 'red')
Study: 23400856
Drug: Homophones of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homophones of the color characters (S+T+) (e.g., hong2, 'flood')
Study: 23400856
Drug: Different-tone homophones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different-tone homophones (S+T-) (e.g., hong1, 'boom')
Study: 23400856
Drug: Characters that
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Characters that shared the same tone but differed in segments with the color characters (S-T+) (e.g., ping2, 'bottle')
Study: 23400856
Drug: Neutral characters
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral characters (S-T-) (e.g., qian1, 'leading through')
Study: 21911098
Drug: Supportive individual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive individual psychotherapy followed by combined psychodynamic and cognitive‐behavioral group therapy (total of 28 sessions).
Study: 11134132
Drug: GHRP-2 administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GHRP-2 administration
Study: 8800308
Drug: Intravenous iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous iloprost 0.5‐2.0 ng/kg/min for 6 h from 8 to 13 days
Study: 1464049
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin pre-treatment
Study: 29433385
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine infusion (bolus 1.5 mg/kg followed by a continuous infusion at the rate of 2 mg/kg/hr until skin closure)
Study: 29433385
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine infusion
Study: 29433385
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% NaCl solution)
Study: 25305156
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of imaging abnormalities (PiB+, small hippocampi, WMLs)
Study: 16550311
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose bolus of tirofiban (10 microg/kg/3 min) with 24‐h infusion at a rate of 0.15 microg/kg/min
Study: 16550311
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose bolus tirofiban (25 microg/kg/3 min)
Study: 9305603
Drug: St Jude-type
Normalized name: ST-36
DrugBank: ST-36 (DB17275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St Jude-type multiagent chemotherapy
Study: 9305603
Drug: St Jude-type
Normalized name: ST-36
DrugBank: ST-36 (DB17275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St Jude-type multiagent chemotherapy (for good-prognosis subgroup)
Study: 8361895
Drug: Molsidomine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (2 mg, single oral dose)
Study: 2423807
Drug: Indoramin plus
Normalized name: indoramin
DrugBank: Indoramin (DB08950)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin plus thiazide diuretic (n = 157)
Study: 26072289
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose escalation (RDE)
Study: 26072289
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose rate brachytherapy boost (HDRB)
Study: 18789492
Drug: JTT‐705 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTT‐705 600 mg/d
Study: 16305570
Drug: Self-administered isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered isoflurane and desflurane
Study: 31175903
Drug: Stereotactic Body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic Body Radiation Therapy (SBRT) for recurrent HCC
Study: 23985260
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus chemotherapy (FP/H)
Study: 23985260
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (FP)
Study: 16650294
Drug: Intrarectal application
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal application of 2% lidocaine gel